Payment overview · 2025
General Payments
$2,006.46
123 reported records · 17 companies
Healthcare provider profile · identity verified
Megan Light Appleby, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAWRENCEVILLE, GA · NPI 1336636497
Verified facts
What the public records show
CMS Open Payments records show Megan Light Appleby, MD received $2,006.46 in general payments during 2025 across 123 reported records.
ABBVIE INC. accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $336.95 | 16.8% | 33 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $255.84 | 12.8% | 15 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $208.86 | 10.4% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $187.70 | 9.3% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $159.53 | 8.0% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $158.18 | 7.9% | 8 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $115.41 | 5.8% | 6 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $108.35 | 5.4% | 7 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $107.15 | 5.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $97.44 | 4.9% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $73.64 | 3.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $68.97 | 3.4% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.44 | 2.6% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $26.37 | 1.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.39 | 0.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.24 | 0.9% | 1 | 2025 |
| Atland Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $15.00 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,006.46 | 123 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $265.33 | 12 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $255.84 | 15 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $208.86 | 12 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $183.69 | 20 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $140.88 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $140.88 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $139.70 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $125.27 | 8 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $115.41 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $113.11 | 4 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $108.35 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $101.77 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $80.86 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $73.64 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.77 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $38.03 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.25 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.11 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $26.37 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE Normalized: orphenadrine citrate aspirin and caffeine |
Drug | Atland Pharmaceuticals, LLC | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| TOLMETIN SODIUM Normalized: tolmetin sodium |
Drug | Atland Pharmaceuticals, LLC | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $12.48 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $12.48 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $12.38 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $7.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 42 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 62 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 38 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
21 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
62 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 194 | 53 |
| Lisinopril | Lisinopril | 187 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 186 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 165 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 134 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 113 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 49 |
| Omeprazole | Omeprazole | 100 | 36 |
| Prednisone | Prednisone | 92 | 67 |
| Clonazepam | Clonazepam | 91 | 19 |
| Ozempic | Semaglutide | 86 | 27 |
| Losartan Potassium | Losartan Potassium | 83 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 83 | 38 |
| Ondansetron Odt | Ondansetron | 78 | 36 |
| Metformin Hcl | Metformin Hcl | 75 | 21 |
| Alprazolam | Alprazolam | 72 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 71 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 40 |
| Tramadol Hcl | Tramadol Hcl | 65 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 22 |
| Mounjaro | Tirzepatide | 62 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 21 |
| Methylprednisolone | Methylprednisolone | 59 | 50 |
| Sertraline Hcl | Sertraline Hcl | 58 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 24 |
| Trazodone Hcl | Trazodone Hcl | 53 | 30 |
| Trulicity | Dulaglutide | 52 | 12 |
| Azithromycin | Azithromycin | 51 | 44 |
| Metformin Hcl Er | Metformin Hcl | 51 | 21 |
| Pregabalin | Pregabalin | 49 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | suppressed |
| Famotidine | Famotidine | 48 | 18 |
| Montelukast Sodium | Montelukast Sodium | 48 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 17 |
| Buspirone Hcl | Buspirone Hcl | 46 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 35 |
| Farxiga | Dapagliflozin Propanediol | 42 | 14 |
| Alendronate Sodium | Alendronate Sodium | 40 | 13 |
| Meloxicam | Meloxicam | 39 | 19 |
| Bupropion Xl | Bupropion Hcl | 38 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 38 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | 11 |
| Azelastine Hcl | Azelastine Hcl | 37 | 22 |
| Simvastatin | Simvastatin | 37 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 37 | 14 |
| Carvedilol | Carvedilol | 36 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 17 |
| Furosemide | Furosemide | 36 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | 11 |
| Jardiance | Empagliflozin | 34 | 11 |
| Eliquis | Apixaban | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 29 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 28 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 12 |
| Lorazepam | Lorazepam | 28 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 21 |
| Allopurinol | Allopurinol | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Naproxen | Naproxen | 25 | 17 |
| Topiramate | Topiramate | 25 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Potassium Chloride | Potassium Chloride | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Cefdinir | Cefdinir | 18 | 18 |
| Cephalexin | Cephalexin | 18 | 17 |
| Diazepam | Diazepam | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 17 |
| Lidocaine | Lidocaine | 17 | suppressed |
| Progesterone | Progesterone, Micronized | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 15 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | 11 |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,006.46 · 123 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, COMIRNATY, EVENITY, FANAPT, FARXIGA, INSPIRE, KISUNLA, KRYSTEXXA, MOUNJARO, NURTEC ODT, NUZYRA, ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, Qelbree, REPATHA, REXULTI, Rybelsus, SYNTHROID, TOLMETIN SODIUM, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, WaveWriter Alpha Prime 16, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error